Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population (vol 189, pg 689, 2021)

被引：0

作者：

De Laurentiis, Michelino ^{[1
]}

Borstnar, Simona ^{[2
]}

Campone, Mario ^{[3
]}

Warner, Ellen ^{[4
]}

Bofill, Javier Salvador ^{[5
]}

Jacot, William ^{[6
]}

Dent, Susan ^{[7
,17
]}

Martin, Miguel ^{[8
]}

Ring, Alistair ^{[9
]}

Cottu, Paul ^{[10
]}

Lu, Janice ^{[11
]}

Ciruelos, Eva ^{[12
]}

Azim, Hamdy A. ^{[13
]}

Chatterjee, Sanjoy ^{[14
]}

Zhou, Katie ^{[15
]}

Wu, Jiwen ^{[15
]}

Menon-Singh, Lakshmi ^{[15
]}

Zamagni, Claudio ^{[16
]}

机构：

[1] Ist Nazl Tumori IRCCS Fdn Pascale, Dept Breast & Thorac Oncol Director, Div Breast Med Oncol, Naples, Italy

[2] Inst Oncol Ljubljana, Ljubljana, Slovenia

[3] Western Canc Inst, Nantes, France

[4] Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada

[5] Virgen Rocio Univ Hosp, Biomed Inst, Seville, Spain

[6] Montpellier Canc Inst, Montpellier, France

[7] Ottawa Hosp, Ctr Canc, Ottawa, ON, Canada

[8] Univ Complutense, CIBERONC, GEICAM, Gregorio Maranon Gen Univ Hosp, Madrid, Spain

[9] Royal Marsden Hosp NHS Fdn Trust, Sutton, Surrey, England

[10] Curie Inst, Paris, France

[11] USC Norris Comprehens Canc Ctr, Los Angeles, CA USA

[12] Univ Hosp 12 Octubre, Clara Campal Comprehens Canc Ctr, HM CIOCC, Madrid, Spain

[13] Cairo Univ, Fac Med, Cairo, Egypt

[14] Tata Med Ctr, Kolkata, India

[15] Novartis Pharmaceut, E Hanover, NJ USA

[16] Azienda Ospedaliero Univ Bologna, Bologna, Italy

[17] Duke Univ, Sch Med, Duke Canc Inst, Durham, NC USA

来源：

BREAST CANCER RESEARCH AND TREATMENT | 2022年 / 191卷 / 01期

关键词：

D O I：

10.1007/s10549-021-06374-6

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：223 / 224

页数：2

共 50 条

[31] Ribociclib plus letrozole in patients with hormone receptor-positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC): Expanded safety analysis of the phase IIIb CompLEEment-1 trial
Lu, Janice
Cottu, Paul
Martin, Miguel
Zamagni, Claudio
Prat, Aleix
Chia, Stephen
Jerusalem, Guy
Rajappa, Senthil
Timcheva, Constanta
Zhukova, Lyudmila
Zhou, Katie
Wu, Jiwen
Menon-Singh, Lakshmi
De Laurentiis, Michelino
CANCER RESEARCH, 2021, 81 (04)
[32] Efficacy and safety of ribociclib (RIB) in combination with letrozole (LET) in patients with estrogen receptorepositive advanced breast cancer (ABC): Secondary and exploratory results of phase 3b RIBECCA study
Decker, T.
Fasching, P. A.
Nusch, A.
Hartkopf, A.
Heinrich, B. J.
Kurbacher, C. M.
Fuchs, R.
Tesch, H.
Krabisch, P.
Huober, J.
Kuemmel, S.
Brucker, S. Y.
Janni, W.
Schneeweiss, A.
Schuler, M.
Fehm, T. N.
Lueftner, D.
Quiering, C.
Kreuzeder, J.
Reinisch, M.
ANNALS OF ONCOLOGY, 2021, 32 : S467 - S468
[33] Palbociclib Plus Letrozole as First-Line Therapy in Postmenopausal Asian Women With Metastatic Breast Cancer: Results From the Phase III, Randomized PALOMA-2 Study
Im, Seock-Ah
Mukai, Hirofumi
Park, In Hae
Masuda, Norikazu
Shimizu, Chikako
Kim, Sung-Bae
Im, Young-Hyuck
Ohtani, Shoichiro
Bartlett, Cynthia Huang
Lu, Dongrui R.
Iyer, Shrividya
Mori, Yuko
Mori, Ave
Gauthier, Eric
Finn, Richard S.
Toi, Masakazu
JOURNAL OF GLOBAL ONCOLOGY, 2019, 5 : 1 - 19
[34] Ribociclib plus letrozole in patients with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2) advanced breast cancer (aBC) with no prior endocrine therapy (ET) for ABC: CompLEEment-1 trial, preliminary results from Spanish population
Salvador, J.
Ciruelos, E. M.
Prat, A.
Jimenez-Rodriguez, B.
de la Cruz, L.
Martinez, N.
Villanueva Vazquez, R.
de Toro, R.
Anton, A.
Moreno, F.
Alvarez, I.
Gavila, J.
Quiroga, V.
Vicente, E.
de la Haba, J.
Gonzalez-Santiago, S.
Diaz, N.
Barnadas, A.
Cantos Sanchez de Ibarguen, B.
Delgado, J. I.
Bellet, M.
Gimeno, A.
Sanz, S.
Martin, M.
CANCER RESEARCH, 2019, 79 (04)
[35] Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women:: Analysis of survival and update of efficacy from the international letrozole breast cancer group
Mouridsen, H
Gershanovick, M
Sun, Y
Pérez-Carrión, R
Boni, C
Monnier, A
Apffelstaedt, J
Smith, R
Sleeboom, HP
Jaenicke, F
Pluzanska, A
Dank, M
Becquart, D
Bapsy, PP
Salminen, E
Snyder, R
Chaudri-Ross, H
Lang, R
Wyld, P
Bhatnagar, A
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (11) : 2101 - 2109
[36] Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: Analysis of survival and update of efficacy from the international letrozole breast cancer group
Buzdar, AU
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (15) : 3199 - 3200
[37] Overall survival subgroup analysis by metastatic site from the phase 3 MONALEESA-2 study of first-line ribociclib plus letrozole in postmenopausal patients with advanced HR+/HER2-breast cancer
O'Shaughnessy, Joyce
Stemmer, Salomon M.
Burris, Howard A.
Yap, Yoon-Sim
Sonke, Gabe
Hart, Lowell
Campone, Mario
Petrakova, Katarina
Winer, Eric P.
Janni, Wolfgang
Conte, Pierfranco
Cameron, David A.
Andre, Fabrice
Arteaga, Carlos
Zarate, Juan Pablo
Chakravartty, Arunava
Taran, Tetiana
Le Gac, Fabienne
Serra, Paolo
Hortobagyi, Gabriel N.
CANCER RESEARCH, 2022, 82 (04)
[38] Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: Analysis of survival and update of efficacy from the international letrozole breast cancer group - Reply
Mouridsen, H
Chaudri-Ross, HA
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (15) : 3200 - 3201
[39] First-line ribociclib plus letrozole in postmenopausal women with HR+, HER2-advanced breast cancer: Tumor response and pain reduction in the phase 3 MONALEESA-2 trial
Janni, Wolfgang
Alba, Emilio
Bachelot, Thomas
Diab, Sami
Gil-Gil, Miguel
Beck, Thaddeus J.
Ryvo, Larisa
Lopez, Rafael
Tsai, Michaela
Esteva, Francisco J.
Zamora Aunon, Pilar
Kral, Zdenek
Ward, Patrick
Richards, Paul
Pluard, Timothy J.
Sutradhar, Santosh
Miller, Michelle
Campone, Mario
BREAST CANCER RESEARCH AND TREATMENT, 2018, 169 (03) : 469 - 479
[40] First-line ribociclib plus letrozole in postmenopausal women with HR+ , HER2− advanced breast cancer: Tumor response and pain reduction in the phase 3 MONALEESA-2 trial
Wolfgang Janni
Emilio Alba
Thomas Bachelot
Sami Diab
Miguel Gil-Gil
Thaddeus J. Beck
Larisa Ryvo
Rafael Lopez
Michaela Tsai
Francisco J. Esteva
Pilar Zamora Auñón
Zdenek Kral
Patrick Ward
Paul Richards
Timothy J. Pluard
Santosh Sutradhar
Michelle Miller
Mario Campone
Breast Cancer Research and Treatment, 2018, 169 : 469 - 479

← 1 2 3 4 5 →